Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An anti-IL-25 antibody is a monoclonal antibody designed to target and neutralize interleukin-25 (IL-25, also known as IL-17E), an upstream alarmin cytokine that plays a critical role in initiating and amplifying type 2 (Th2) immune responses. By binding to IL-25, the antibody prevents its interaction with the heterodimeric receptor complex composed of IL-17RA and IL-17RB. This blockade suppresses the downstream activation of type 2 innate lymphoid cells (ILC2s) and Th2 helper T cells, thereby inhibiting the release of key pro-inflammatory cytokines such as IL-4, IL-5, and IL-13. Anti-IL-25 antibodies are being investigated for the treatment of various Th2-mediated inflammatory and allergic diseases, including asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-IL-25 antibody.